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Decreased peroxisome proliferator-activated receptor gamma (PPARγ) activity is thought
to have a major role in preeclampsia through abnormal placental development. However,
the role of PPARγ in adaptation of the uteroplacental vasculature that may lead to placental
hypoperfusion and fetal growth restriction during pregnancy is not known. Here, pregnant
Sprague–Dawley rats (n = 11/group) were treated during the second half of pregnancy
with the PPARγ inhibitor GW9662 (10mg/kg/day in food) or vehicle. Pregnancy outcome
and PPARγ mRNA, vasodilation and structural remodeling were determined in maternal
uterine and mesenteric arteries. PPARγ was expressed in uterine vascular tissue of both
non-pregnant and pregnant rats with ∼2-fold greater expression in radial vs. main uterine
arteries. PPARγ mRNA levels were significantly higher in uterine compared to mesenteric
arteries. GW9662 treatment during pregnancy did not affect maternal physiology (body
weight, glucose, blood pressure), mesenteric artery vasodilation or structural remodeling
of uterine and mesenteric vessels. Inhibition of PPARγ for the last 10 days of gestation
caused decreased fetal weights on both day 20 and 21 of gestation that was associated
with impaired vasodilation of radial uterine arteries in response to acetylcholine and
sodium nitroprusside. These results define an essential role of PPARγ in the control
of uteroplacental vasodilatory function during pregnancy, an important determinant of
blood flow to the placenta and fetus. Strategies that target PPARγ activation in the
uterine circulation could have important therapeutic potential in treatment of pregnancies
complicated by hypertension, diabetes or preeclampsia.
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INTRODUCTION
Preeclampsia, a life-threatening complication of human preg-
nancy characterized by proteinuria and the new-onset of hyper-
tension after 20 weeks of gestation, is a major cause of maternal
and fetal morbidity and mortality worldwide (Roberts, 1998;
Alexander et al., 2001; Sibai et al., 2005). Although the etiol-
ogy of this pregnancy-related disease remains unknown, placental
hypoxia/ischemia due to shallow placentation and reduced uter-
ine blood flow is considered an essential event triggering sys-
temic hypertension and intrauterine growth restriction (Roberts
et al., 2003; Gilbert et al., 2008). During normal pregnancy, the
uterine circulation undergoes considerable structural and func-
tional changes to facilitate a large increase in uterine blood
flow necessary for successful pregnancy (Sibai et al., 2005; Osol
and Mandala, 2009). However, during preeclampsia, this cir-
culation is significantly affected due to decreased vasodilator
production and outward remodeling of uterine spiral vessels
(Roberts, 1998; Sibai et al., 2005; Gilbert et al., 2008; Burton
et al., 2009). These structural and functional abnormalities in the
uteroplacental bed during preeclampsia are likely important for
the progression of placental hypoperfusion associated with the
condition.
Peroxisome proliferator-activated receptor gamma (PPARγ)
is a ligand-activated nuclear hormone receptor that upon acti-
vation, heterodimerizes with retinoid-X-receptor. This complex
then binds to DNA-specific sequences to promote transcrip-
tion of target genes (Desvergne and Wahli, 1999; Marx et al.,
2004; Desvergne et al., 2006). PPARγ is extensively expressed
in white adipose tissue and plays a critical role in the regula-
tion of adipocyte differentiation and function (Desvergne et al.,
2006). PPARγ also has an important role in pregnancy. Studies
using PPARγ-null mice unexpectedly revealed a vital role of these
receptors in placental development. PPARγ-null placentas exhibit
abnormal terminal differentiation of the trophoblast and defi-
cient placental vascularization leading to embryonic lethality by
mid-gestation. Restoration of PPARγ gene via chimeras resulted
in rescue of mutant embryos indicating that PPARγ deficiency is
the major cause of fetal death (Barak et al., 1999; Kubota et al.,
1999). Recent studies have also demonstrated that PPARγ expres-
sion has an essential role in trophoblast differentiation, invasion
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andmetabolism in rodent and human placenta (Asami-Miyagishi
et al., 2004; Fournier et al., 2007; Barak et al., 2008; Giaginis et al.,
2008).
There is compelling evidence to suggest an association between
PPARγ and preeclampsia. Circulating activators of PPARγ are
reduced in preeclamptic pregnancy weeks before the onset of
maternal symptoms (Waite et al., 2000, 2005). In addition,
women with Pro467Leu mutation, a dominant negative muta-
tion of PPARγ, had pregnancies complicated with gestational
diabetes and severe preeclampsia (Barroso et al., 1999). Recent
studies in rat models also suggest an important role for PPARγ in
preeclampsia. Inhibition of PPARγ during pregnancy in rats with
the ligand inhibitor T0070907 caused key features of preeclamp-
sia to develop, including elevated mean arterial pressure, pro-
teinuria, systemic endothelial dysfunction, and reduced fetal
weight (McCarthy et al., 2011a). In addition, treatment with
the PPARγ activator rosiglitazone in a placental ischemia model
of preeclampsia ameliorated hypertension in pregnant rats and
improved mesenteric artery vasodilation, suggesting PPARγ as
a potential therapeutic target in the treatment of preeclampsia
(McCarthy et al., 2011b).
PPARγ is also expressed in vascular tissue and shown to
have a significant role in the cardiovascular system (Law et al.,
2000; Calnek et al., 2003; Kanie et al., 2003; Bagi et al., 2004).
Inhibition of PPARγ causes inward remodeling, oxidative stress
and endothelial dysfunction of arteries independent of changes in
blood pressure (Sigmund, 2010). However, in spite of the well-
documented function of PPARγ in placental development and
its association with preeclampsia, expression of these receptors
and their role in the control of uteroplacental blood flow dur-
ing pregnancy remains unknown. In this study, we hypothesized
that decreased activity of PPARγ impairs maternal uteroplacental
remodeling and vasodilation during pregnancy resulting in fetal
growth restriction and abnormal placentation. Thus, the objec-
tives of the present study were to (1) characterize the effect of
PPARγ inhibition with oral administration of GW9662, a selec-
tive ligand inhibitor of PPARγ, on maternal and fetal pregnancy
outcome; (2) evaluate endothelial function of uteroplacental
and mesenteric resistance arteries under conditions of decreased
PPARγ activity during second half of rat pregnancy, and (3) to
explore the effect of GW9662 on uterine vascular growth and
mechanical properties of uteroplacental and mesenteric arteries.
METHODS
ANIMALS
Pregnant (6–8 days) Sprague–Dawley rats (11–12 weeks of age)
were purchased from Charles River Laboratories ( St. Constant,
QC, Canada) and housed in the animal care facility at the
University of Vermont. Animals were randomly selected and
treated with either the PPARγ inhibitor GW9662 (10mg/kg/day
for 10 days in food; n = 11) or vehicle (n = 11). Treatment with
GW9662 or vehicle was started at day 10 of pregnancy. The dose
of GW9662 (10mg/kg/day) was higher than has been reported in
other studies (3mg/kg/day; Bagi et al., 2004) due to higher acti-
vation of PPARγ in pregnancy (Waite et al., 2000). GW9662 is a
highly specific irreversible inhibitor of PPARγ and a valuable tool
for determining PPARγ receptor-mediated functions in different
biological systems (Leesnitzer et al., 2002). Rats were studied on
day 20 (n = 8) or 21(n = 3) of pregnancy. All experiments were
conducted in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals, and all pro-
tocols were approved by the Institutional Animal Care and Use
Committee of the University of Vermont.
BLOOD PRESSURE AND GLUCOSE MEASUREMENTS
Blood pressures (systolic, diastolic and mean) were measured
every 2–3 days during treatment by tail cuff as previously
described (Chan et al., 2010). Blood glucose levels were deter-
mined every other day using a Freestyle glucometer.
UTERINE VASCULAR DIMENSIONS AND PREGNANCY OUTCOME
On day 20 (21) of pregnancy, rats were euthanized under anes-
thesia. The mesentery with vasculature, and the gravid uterus
and uterine vasculature were carefully removed and placed in a
dissecting dish containing cold, physiologic salt solution (PSS).
Morphometric measurements of the unstretched uterine vascula-
ture of both uterine horns were completed as previously described
(Phillips et al., 2012). After morphometric measurements, fetuses
and their placentas were individually weighed without mem-
branes and umbilical cords. Fetal outcome of day 20 and 21
control and treated pregnant rats was characterized separately
as there is a significant difference in fetal and placental weights
between day 20 and 21. Also, due to progressive growth of mater-
nal uterine vasculature during the last 5 days of rat pregnancy,
all morphometric and structural vascular measurements were
performed using vessels from 20 day pregnant rats.
RADIAL UTERINE ARTERY (RUA) AND MESENTERIC ARTERY (MA)
VASODILATION
In rodent and human pregnancy with hemochorial placenta-
tion, RUAs are the major site of uteroplacental vascular resistance
(Moll, 2003). Thus, these are key arteries controlling utero-
placental blood flow. Second-order RUAs feeding the placenta
(uteroplacental) were carefully dissected and used for in vitro
experimentation as previously described (Gokina and Goecks,
2006). Uteroplacental radial arteries from late pregnant rats can
develop vasoconstriction (myogenic tone) in response to eleva-
tions of pressure exceeding 50mmHg. To avoid development of
myogenic tone and its interference with phenylephrine-induced
constriction, arteries were pressurized at 50mmHg. After a 1 h
equilibration period and elevation of intraluminal pressure from
10 to 50mmHg, phenylephrine (PE) was applied in increasing
concentrations (1–3 doses) to produce a constriction of 50–70%
of the initial diameter. Following stabilization of diameter, acetyl-
choline (ACh) was added to the bath in increasing concentrations
to assess endothelial function. ACh was washed out and the
nitric oxide synthase (NOS) inhibitor nitro-L-arginine (L-NNA;
200μmol/l) was added. Vessels were again pre-constricted with
PE and the nitric oxide (NO) donor sodium nitroprusside (SNP)
was applied in increasing concentrations to assess smooth mus-
cle responsiveness to NO. Finally, a combination of papaverine
(100μmol/l) and diltiazem (10μmol/l) was added to obtain fully
relaxed diameters and perform passive measurements for assess-
ment of mechanical properties. ACh- or SNP-induced vasodi-
lation was expressed as the percentage of maximal vasodilation
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in response to papaverine and diltiazem (Dmax). Similar parallel
experiments were performed using 3rd order MAs dissected out
from control (n = 8) and GW9662-treated (n = 8) rats.
To characterize the effect of GW9662 on endothelium-
derived hyperpolarizing factor (EDHF)-mediated vasodilation,
ACh effects were also tested on RUA pre-treated with 200μmol/l
L-NNA and 10μmol/l indomethacin for 20min before testing the
effects of PE and ACh to inhibit endogenous production of NO
and prostacyclin.
PASSIVE MECHANICAL PROPERTIES OF ARTERIES
Changes in passive mechanical properties (distensibility, stress-
strain relationships) and remodeling (inner and outer diameters,
wall thickness) were measured for arteries from 20 day preg-
nant rats under fully relaxed conditions, as previously described
(Phillips et al., 2012). Radial uterine arteries (RUA) were given
papaverine (100μmol/l) and diltiazem (10μmol/l) to fully relax
smooth muscle and obtain passive measurements. Lumen diam-
eter changes in response to stepwise elevation in intralumi-
nal pressure from 5 to 125mmHg were monitored with the
SoftEdge Acquisition System (IonOptix, Milton, MA). Arterial
wall thickness (h) was measured from images of pressurized
arteries after stabilization of the lumen diameter (D) at each
specific level of pressure. For the calculation of circumferential
wall stress, intraluminal pressure was converted from mmHg to
N/m2 (1mmHg= 1.334 × 102 N/m2). Circumferential stress, (σ)
was calculated using the equation: σ = PxD/2h. Circumferential
strain (ε) was calculated according to the following equation:
ε = (D − D5)/D5, where D5 represents the lumen arterial diam-
eter at the lowest (5mmHg) intraluminal pressure. The rate
constant of an exponential function fitted to stress-strain curve
(stiffness coefficient β) for each artery was determined using
SigmaPlot software program and used to compare stress-strain
relationships between two groups of arteries.
Similarly, changes in passive arterial diameters and vessel wall
thickness in response to stepwise elevation in intraluminal pres-
sure were measured from fully relaxed 3rd order mesenteric
arteries of control and GW9662-treated rats.
TISSUE COLLECTION AND QUANTITATIVE RT PCR
RUAs and main uterine arteries were collected from non-
pregnant (n = 6) and untreated late-pregnant (n = 7) rats for
real-time PCR analysis of PPARγ expression. In addition, expres-
sion of PPARγ was compared in main uterine arteries and sec-
ond order MAs from 20 day pregnant rats (n = 3) as well as
in main uterine arteries of GW9662- and vehicle-treated rats.
Placentas were collected from control and treated rats to deter-
mine the expression of soluble fms-like tyrosine kinase 1(sFlt-1)
mRNA. Visceral mesenteric fat was collected from vehicle- and
GW9662-treated late pregnant rats (n = 11) for real-time PCR
analysis of leptin expression to assess treatment efficiency. All
PCR was performed as previously described (Chan et al., 2010).
RNA was extracted from arteries utilizing a TRIzol (Invitrogen)
extraction protocol and further purified using a RNeasy Micro
Kit (Qiagen). All samples were quantified using a Nanodrop
Spectrophotometer and RNA integrity was assessed on the
Agilent 2100 Bioanalyzer (Agilent Technologies). Fifty ng of total
RNAwas reverse transcribed using the iScript cDNA Synthesis Kit
(Biorad). QPCR reactions were done using 150 nM of forward
and reverse primers in Power Sybrgreen Master Mix (Applied
Biosystems) with 1μl of cDNA template. Target mRNA tran-
scripts for PPARγ, leptin and two housekeeping genes (Hprt
and Ywhaz) were amplified using an ABI Prism 7000 Sequence
Detection System. Relative quantification was determined using
the comparative Ct method (2−CT). Standard curves were
generated for each primer set to ensure that primer efficiencies
were within 10% of each other to allow for this analysis choice.
Relative target mRNA values were normalized using the mean
of the control gene quantities and calibrated to a control sam-
ple in each group. Negative water controls were run for each
primer set to ensure no contamination in the reagents and that
no secondary primer structures were amplified. In each primer
set at least one primer was designed over an exon-exon junc-
tion. We used the following primers: PPARγ_F (GTCTCACAAT
GCCATCAGGTTT); PPARγ_R (TCAGCGGGAAGGACTTTAT
GTAT); Hprt_F (CAGTCCCAGCGTCGTGAT); Hprt_R (CA
AGTCTTTCAGTCCTGTCCATAA); Ywhaz_F (GCAACGACGT
ACTGTCTCTTTTGG); Ywhaz_R (GTCCACAATTCCTTTCT
TGTCATC); Leptin F (TTTCACACACGCAGTCGvGTATCC);
Leptin R (AGATGGAGGAGGTCTCGCAG).
sFlt-1 F (TGTGGCACCCCTGTCACTACA); sFlt-1 R (ACCGT
CTTATTGGTTCCTTCTATGACC).
UTERINE VASCULAR DIMENSIONS
A stereomicroscope (Zeiss Stemi 2000-C) with a calibrated retic-
ule was used to determine the length of the main uterine artery,
the distance between the main uterine artery and placenta or
myometrium in the center of each uterine horn.
SOLUTIONS AND DRUGS
The PSS used for isolated artery experiments contained (mmol/l):
119NaCl, 4.7 KCl, 24.0NaHCO3, 1.2 KH2PO4, 1.6 CaCl2,
1.2MgSO4, 0.023 EDTA, and 11.0 glucose, pH = 7.4 (maintained
by aeration with 5% O2, 10% CO2 and 85% N2). All chemi-
cals were purchased from Sigma Chemical Co. (St. Louis, MO).
GW9662 was purchased from Cayman Chemical (Ann Arbor,
MI, USA). Diltiazem was prepared as a 10mmol/L stock solution
in deionized water and kept (1–2 weeks) refrigerated until use.
Indomethacin was prepared in ethanol and L-NNA was dissolved
in PSS. ACh, PE, SNP and papaverine were dissolved in deionized
water, prepared and used on the day of the experiment.
STATISTICAL ANALYSIS
Arterial diameter and pressure were simultaneously recorded
with an IonOptix data acquisition program and imported into
SigmaPlot program for graphical representation, calculations,
and statistical analysis. Because of oscillatory pattern of the
responses in arterial diameter, we calculated a mean value for
diameters that represents average data points over period of
15–20 s obtained using IonOptix software, and includes 1–3
oscillations when present. An unpaired Student’s t-test or Two-
Way repeated measures ANOVA with a Holm-Sidak post-hoc test
(SigmaPlot software) was used to compared groups. Significant
differences were defined as p < 0.05. Data are presented as
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mean ± SEM, where n is the number of arterial segments stud-
ied. One artery per animal was used for reactivity and structural
measurements.
RESULTS
MATERNAL AND FETAL OUTCOME
GW9662 treatment of pregnant rats did not affect maternal
blood glucose levels, body weight or blood pressure (Table 1).
Oral administration of GW9662 during the second half of preg-
nancy resulted in significantly reduced fetal weights on day 20
(2.21 ± 0.02 g vs. 2.30 ± 0.02 g; p < 0.05) and 21 (3.40 ± 0.07 g
vs. 3.75 ± 0.03 g; p < 0.01) of pregnancy. Placental weights were
similar between control and GW9662-treated rats on 20 day of
pregnancy (0.45 ± 0.01 g vs. 0.44 ± 0.01 g; p > 0.05) but were
significantly increased in the treated group on day 21 of preg-
nancy (0.54 ± 0.02 g vs. 0.48 ± 0.01 g; p < 0.01). There were no
significant differences in the number of fetal resorptions (0.3 ±
0.2 vs. 0.8 ± 0.4; p > 0.05) or litter size (14.0 ± 0.6 vs. 14.2 ± 0.9;
p > 0.05) between GW9662-treated and control groups, respec-
tively (Table 1).
PPARγ EXPRESSION IN UTERINE AND MESENTERIC ARTERIES
PPARγ is expressed in vascular cells and shown to have a role
in regulating vascular structure and function (Sigmund, 2010).
However, if PPARγ is expressed in uterine vasculature and if
PPARγ expression is modulated during pregnancy has not been
shown. Thus, we compared relative mRNA expression of PPARγ
in main uterine and RUAs from non-pregnant (n = 6) and late-
pregnant rats (n = 7) using quantitative PCR methodology. As
shown in Figure 1A, PPARγ was expressed in both types of uter-
ine arteries, with a significantly greater expression in the smaller
RUAs compared to largermain uterine arteries. Pregnancy did not
modulate the expression of the PPARγ in both types of vessels.
When compared to vessels from a non-reproductive organ, rela-
tive PPARγmRNA levels were significantly higher inmain uterine
artery compared to MAs of late-pregnant rats (Figure 1B).
PLACENTAL sFlt-1 EXPRESSION
sFlt-1mRNA levels were determined in the placentas from control
(n = 7) and GW9662-treated (n = 8) rats. There was no signifi-
cant increase in total sFlt-1 expression in GW9662-treated rats
compared to controls (0.81 ± 0.11 vs. 0.74 ± 0.08 relative to a
sample from a control rat).
LEPTIN EXPRESSION IN ADIPOSE TISSUE WITH GW9662 TREATMENT
To ascertain that treatment with GW9662 was effective at inhibit-
ing PPARγ, leptin mRNA expression was measured in adipose
tissue where both PPARγ and leptin are highly expressed. Leptin
is a well-known PPARγ target gene (Desvergne et al., 2006). In
FIGURE 1 | (A) Bar graphs showing relative expression of PPARγ in uterine
arteries of non-pregnant and pregnant rats. PPARγ mRNA was detected in
both types of uterine arteries. A comparison between main and radial
uterine arteries demonstrates significantly greater PPARγ expression in
smaller radial resistance arteries of non-pregnant and late pregnant rats.
mRNA is expressed relative to the main uterine artery sample from a
control rat. ∗p < 0.05 vs. main uterine artery. (B) Higher expression of
PPARγ in uterine compared to mesenteric vasculature of late pregnant rats.
Quantitative RT-PCR results showing relative expression of PPARγ mRNA in
mesenteric and main uterine arteries obtained from the same rats (n = 4).
Results analyzed using the ddct method and normalized to Ywhaz. mRNA
is expressed relative to the sample from main uterine artery. (C) Bar graph
showing relative leptin mRNA expression, a PPARγ target gene, in adipose
tissue from control and GW9662-treated pregnant rats. GW9662 treatment
caused a significant increase in leptin mRNA, demonstrating that treatment
to inhibit PPARγ was effective. ∗p < 0.05 vs. control.
PPARγ+/− mice where the activity of the receptors is moderately
reduced, leptin mRNA in white adipose tissue and circulating lev-
els of leptin were higher compared to wild type animals (Kubota
et al., 1999). On the other hand, PPARγ activators reduced the
expression of leptin receptors in adipose tissue (Kallen and Lazar,
Table 1 | Maternal physiological parameters and pregnancy outcome of Sprague–Dawley rats.
Animal Maternal Blood glucose BP systolic, BP diastolic, BP Mean Litter size Number of
weight, (g) (mg/dL) (mmHg) (mmHg) (mmHg) (number of pups) resorptions
Untreated (n = 11) 377 ± 9 87 ± 4 117± 6 87 ± 5 95± 5 14± 0.9 0.8± 0.4
GW9662-treated (n = 11) 387 ± 6 88 ± 4 116± 4 86 ± 4 96± 4 14± 0.6 0.3± 0.2
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1996). Based on these observations, leptin expression was selected
as an indicator of PPARγ activity in this study. Figure 1C shows
that leptin expression was significantly increased with GW9662
treatment compared to vehicle, demonstrating that inhibition of
PPARγ during the last half of pregnancy was effective at altering
PPARγ-specific gene expression. Thus, treatment with GW9662
appeared to inhibit PPARγ as expected.
GW9662 EFFECT ON RUA REACTIVITY
The effect of PPARγ inhibition on endothelial function of RUAs
was determined as these vessels are the site of vascular resis-
tance in the uteroplacental bed and thus an effect on their
vasodilator properties could influence uterine blood flow. The
vasodilator effect of ACh was compared between RUAs from
control and GW9662-treated animals after pre-constricting with
PE by 63 ± 4% (Control, n = 7) and 57 ± 2% (GW9662,
n = 8) of their initial diameters. Initial diameters of RUAs of con-
trol (187.7 ± 6.5μm) and GW9662-treated (177.3 ± 13.8μm)
rats were not significantly different from their passive diameters
measured in the presence of papaverine and diltiazem (192.8 ±
5.1μm and 177.4 ± 13.4μm, in RUAs of control and treated rats,
respectively). Figures 2A,B show representative diameter changes
of arteries from control and GW9662-treated rats in response
to cumulative application of ACh. These data, summarized in
Figure 2C, demonstrate that inhibition of PPARγ with GW9662
decreased ACh vasodilation of RUA.
We also characterized the effect of GW9662 treatment on NO-
and prostacyclin independent (EDHF-mediated) vasodilation of
RUA. Figure 2D demonstrates a significant attenuation of EDHF-
mediated vasodilation to ACh in vessels from rats pre-treated with
GW9662 in the presence of L-NNA and indomethacin.
Because reactivity of vascular smooth muscle cells (SMCs)
to NO might be decreased by exposure of rats to GW9662, we
compared the response of RUAs to the NO donor SNP. PPARγ
controls NO production in vascular endothelium (Kleinhenz
et al., 2009). Chronic exposure of pregnant rats to GW9662 may
modulate basal NO generation with consequent change in sensi-
tivity of soluble guanylate cyclase (sGC) to NO in SMCs of uterine
arteries (Moncada et al., 1991). To eliminate the differences in
NO sensitivity of sGC in control and treated vessels and to deter-
mine whether mechanisms of NO-induced SMC relaxation is
modulated by GW9662 treatment, endogenous NO production
was inhibited with L-NNA. Figures 3A,B show representative
diameter changes of arteries from control and GW9662-treated
rats in response to cumulative application of SNP. A summary
graph on Figure 3C demonstrates that vasodilation to SNP was
significantly impaired by GW9662 treatment.
MATERNAL UTERINE VASCULAR REMODELING
To characterize the effect of PPARγ inhibition on the growth of
the maternal uterine vasculature, measurements of the mesome-
trial uterine arcade were taken from both uterine horns of
20 day pregnant GW9692-treated (n = 8) or control (n = 8) rats
immediately after euthanasia as previously described (Phillips
et al., 2012). There were no differences in the length of the main
uterine artery (79.7 ± 3.4 vs. 80.6 ± 2.0mm) or the distance
from the main uterine artery to the placenta (12.3 ± 0.5 vs.
12.2 ± 0.5mm) or to the myometrium (14.6 ± 0.6 vs. 14.9 ±
0.6mm) between control and GW9662-treated rats, respectively.
EFFECT OF GW9662 TREATMENT ON PASSIVE MECHANICAL
PROPERTIES OF UTEROPLACENTAL ARTERIES
Arterial wall thickness and passive lumen diameters, indica-
tors of circumferential vascular remodeling, were measured from
RUAs of 20 day pregnant rats pressurized at 5–125mmHg.
Despite decreases in vasodilatory responses, there was no effect of
GW9662 treatment on wall thickness or passive lumen diameters
(Figures 4A,B). Passive distensibility of uteroplacental arteries
from GW9662-treated and control animals was also not signifi-
cantly different between groups (not shown).
Finally, the effect of GW9662 administration during preg-
nancy on passive mechanical properties of uteroplacental arteries
was characterized by the stress-strain relationship and comparing
the stiffness coefficient β for each artery. There were no changes
in the stress-strain relationship or stiffness coefficient β in RUAs
of GW9662-treated vs. control rats (Figures 4C,D).
GW9662 EFFECT ON REACTIVITY AND STRUCTURE OF MA
Effect of GW9662 treatment on MA responses to ACh and SNP
was determined in parallel experiments. There were no significant
differences in ACh- and SNP-induced vasodilation between two
groups of vessels (Figures 5A,B). Similarly, GW9662 treatment
did not affect passive lumen diameters and wall thickness of
MA (Figures 5C,D). Thus, the effect of PPARγ inhibition on
vasodilation was specific for RUAs.
DISCUSSION
This study investigated the role of PPARγ in uteroplacental vascu-
lar adaptation to pregnancy and fetal growth by inhibiting PPARγ
during the second half of rat pregnancy and assessing fetal out-
come, uterine vascular remodeling and vasodilatory function. We
found that PPARγ was highly expressed in the uterine circulation
and that expression of PPARγ was ∼2-fold greater in radial vs.
main uterine arteries, suggesting amore prominent role of PPARγ
in smaller resistance arteries vs. larger conduit vessels. Inhibition
of PPARγ with administration of GW9662 during rat pregnancy
resulted in fetal growth restriction and decreased vasodilation of
uterine resistance arteries to both endothelium-dependent (ACh)
and –independent (SNP) agents. However, growth of the mater-
nal uterine vasculature and passive mechanical properties were
not modified by GW9662 administration at this time point in
gestation. Together, these results suggest that PPARγ inhibition
during the last half of pregnancy selectively affected uterine vascu-
lar vasodilatory function without affecting structural remodeling.
The association of PPARγ inhibition with fetal growth restric-
tion could implicate vasodilation of the uteroplacental arteries
over remodeling as a key mechanism controlling fetal weight dur-
ing the last half of gestation. In addition, these results implicate
PPARγ activation as an important mechanism regulating uterine
artery vasodilatory function during pregnancy.
In the present study, a short-term treatment of pregnant
rats with GW9662 resulted in significant reduction in fetal
weights on days 20 and 21 of pregnancy. The association
between decreased PPARγ activation or expression and fetal
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FIGURE 2 | Chronic inhibition of PPARγ during the second half of
rat pregnancy resulted in impairment of uterine vasodilation.
Representative changes in the arterial diameter of radial
uteroplacental arteries from a control (A) and a GW9662-treated (B)
pregnant rats induced by cumulative application of ACh. The arteries
were pre-constricted with phenylephrine before testing ACh. Dotted
lines show maximal diameters (Dmax) of the arteries dilated in a
relaxing solution containing 10μmol/l diltiazem and 100μmol/l
papaverine. (C) Graph summarizing the effect of oral administration
of GW9662 during pregnancy on concentration-dependent dilation of
uteroplacental arteries to ACh; (D) Graph showing attenuation of
EDHF-mediated uterine vasodilation induced by GW9662 treatment.
The arteries were pre-treated for 20min with 200μmol/l L-NNA and
10μmol/l indomethacin before testing ACh. ∗p < 0.05 vs. control.
growth restriction has been demonstrated in several condi-
tions. Recent data indicate that circulating activators of PPARγ
are reduced in human pregnancy complicated with preeclamp-
sia that is often associated with intrauterine growth restriction
(IUGR) (Wieser et al., 2008). PPARγ expression was found to
be diminished in human placentas of small for gestational age
fetuses (Diaz et al., 2012). In addition, maternal glucocorti-
coid exposure results in a marked reduction in PPARγ expres-
sion in the labyrinth zone of rat placenta that is also associ-
ated with restricted fetal growth (Hewitt et al., 2006). Recently,
reduced fetal weight similar to what has been reported in the
present study, was also found in pregnant rats treated with
T0070907, another PPARγ antagonist (McCarthy et al., 2011a).
Collectively these findings suggest an essential link between
activity of PPARγ and fetal growth in animal and human
pregnancy.
Reduced uterine blood flow during pregnancy is associ-
ated with fetal growth restriction (Zimmermann et al., 1997;
Alexander et al., 2001; Isler et al., 2003; Sibai et al., 2005). It is
well-documented that intrauterine growth restriction caused by
hypertensive pregnancy, preeclampsia or high altitude hypoxia,
is associated with endothelial dysfunction of maternal uterine
arteries (Mateev et al., 2003; Wareing et al., 2005; Kusinski et al.,
2012). Treatment with sildenafil improves both maternal uterine
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FIGURE 3 | Attenuation of sodium nitroprusside (SNP)-induced
vasodilation of radial uteroplacental arteries by PPARγ inhibition
during rat pregnancy. Representative tracings showing dilatation of
uteroplacental arteries from control (A) and GW9662-treated (B)
pregnant rats induced by a cumulative application of SNP. Dotted
lines indicate the maximal arterial diameters (Dmax) in the
presence of papaverine and diltiazem. (C) Graph summarizing the
effect of oral administration of GW9662 during pregnancy on
concentration-dependent dilation of uteroplacental arteries to SNP.
∗p < 0.05 vs. control.
vasodilation and fetal growth in a mouse model of preeclamp-
sia (Stanley et al., 2012). These data strongly support impaired
uteroplacental vasodilation as a cause of reduced placental per-
fusion and intrauterine growth restriction in animal and human
pregnancies.
Impaired dilatation of the maternal uterine vasculature
may be one of the underlying mechanisms of abnormal fetal
growth in our study. Indeed, RUAs from GW9662-treated ani-
mals were less responsive to both the endothelium-dependent
vasodilator ACh and the endothelium-independent vasodila-
tor SNP, suggesting an effect of PPARγ on endothelial and
SMC function. Despite decreased vasodilator function with
GW9662, there was no effect of PPARγ on uterine vascu-
lar remodeling suggesting uterine vasodilation as an important
mechanism in regulating uteroplacental blood flow and fetal
growth.
Recent studies demonstrate that PPARγ plays a pivotal role in
regulating vascular structure in other circulations (Bishop-Bailey,
2000; Marx and Walcher, 2007; Nicolakakis and Hamel, 2010;
Sigmund, 2010). In male mice, a dominant-negative mutation in
PPARγ resulted in hypertrophy and inward remodeling in cere-
bral arterioles (Beyer et al., 2008). In addition, a previous study
from our lab found that GW9662 treatment resulted in vessel wall
hypertrophy of cerebral arteries of non-pregnant and pregnant
females (Chan et al., 2010). In the present study, similar exposure
of pregnant rats to GW9662 induced no significant change in vas-
cular structure of uterine vessels, suggesting a differential effect
of PPARγ in uterine vs. cerebral vascular beds during pregnancy.
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FIGURE 4 | Passivemechanical properties of radial uteroplacental arteries
from control and GW9662-treated rats. (A,B) Arterial wall thickness and
passive arterial diameters as a function of intraluminal pressure. (C,D)
Stress-strain relationship and stiffness coefficients were determined for radial
uteroplacental arteries from control and GW9662-treated rats. All
measurements were taken from arteries of 20 day pregnant rats.
This is not surprising considering that the uterine vasculature, in
contrast to cerebral vessels, is markedly enlarged over the course
of pregnancy that may offset the negative effects of decreased
PPARγ activity on their structure. Alternatively, the mechanisms
that regulate uterine artery expansion during pregnancy may not
be under control of PPARγ as in other vascular beds.
To our knowledge, this is the first study to show that PPARγ
mRNA is present in the wall of maternal non-pregnant and preg-
nant uterine vasculature. PPARγ appears to regulate vascular
function of uterine arteries during pregnancy since its inhi-
bition results in impaired vasodilatory capacity. Endothelium-
dependent and endothelium-independent uterine vasodilation
was reduced indicating that both endothelial and SMC function is
impaired in pregnant rats chronically exposed to PPARγ inhibitor
GW9662. PPARγ are expressed in vascular endothelium where
they control expression of multiple genes regulating cell adhe-
sion, oxidative stress, PKC and NO production (Sigmund, 2010).
Previously, we have shown that EDHF importantly contributes
to uterine vasodilation and is mediated by Ca2+-dependent
activation of endothelial intermediate and small conductance
potassium channels (Gokina et al., 2010). In this study, we
demonstrated that NO- and prostacyclin-independent uterine
vasodilation was reduced by GW9662 treatment. Exact causes and
mechanisms of impaired EDHF-mediated response by chronic
inhibition of PPARγ in our study remain unknown and may be
induced by increased generation of peroxynitrite (Sharma et al.,
2013). Inhibitory effect of peroxynitrite on EDHF-mediated coro-
nary vasodilation was recently demonstrated (Liu et al., 2006).
It has been shown that disruption of endothelial PPARγ
resulted in endothelial dysfunction due to impaired produc-
tion of NO and induction of oxidative stress (Kleinhenz et al.,
2009). These mechanisms may also contribute to reduced
ACh-induced vasodilation in our study. Inhibition of oxida-
tive stress is one of the key mechanisms of PPARγ protec-
tive effects in the vascular wall (Bishop-Bailey, 2000; Bagi
et al., 2004; Marx and Walcher, 2007; Matsumoto et al., 2008;
Ketsawatsomkron et al., 2010; Sigmund, 2010; McCarthy et al.,
2011b). Cerebrovascular dysfunction in mice with a dominant
negative mutation of PPARγ was reversed by the superoxide
scavenger tempol (Ketsawatsomkron et al., 2010).
Endothelium-independent SNP-induced vasodilation was sig-
nificantly attenuated by chronic exposure of pregnant rats
to GW9662 that suggests impairment of mechanisms medi-
ating NO-induced smooth muscle relaxation in the maternal
uterine vasculature. PPARγ are expressed in vascular SMCs,
and interference with PPARγ in SMCs resulted in systemic
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FIGURE 5 | Chronic inhibition of PPARγ with GW9662 during
the second half of rat pregnancy produced no significant
changes in ACh- and SNP-induced vasodilation (A,B), and
passive mechanical properties (C,D) of mesenteric resistance
arteries. Arteries were pre-constricted with phenylephrine before
testing ACh or SNP. Vasodilation is expressed as a percentage
of maximal response to application of papaverine and diltiazem
(Dmax).
hypertension in part due to attenuation of endothelium-
dependent and independent vasodilation (Halabi et al., 2008).
Dominant negative mutation of PPARγ in smooth muscle
resulted in enhanced myogenic tone through increased activa-
tion of PKC and PKC-dependent inhibition of large conductance
Ca2+-activated potassium channels (BKCa) in mice resistance
vasculature (Ketsawatsomkron et al., 2012). BKCa channels are
important target of NO-cGMP-PKG signaling cascade in vascular
smooth muscle. Whether dysfunction of BKCa channels underlies
reduced NO-mediated uterine vasodilation in our study remains
to be determined.
Finally, due to systemic application of GW9662, indirect effects
of PPARγ inhibition in adipose or placental tissues on uterine vas-
cular function cannot be excluded. In the future studies it seems
important to define the mechanisms and pathways involved in
vasodilation controlled by PPARγ in the maternal uteroplacental
circulation.
We were unable to detect any significant changes in maternal
weight, blood pressure or glucose levels in response to administra-
tion of GW9662 during pregnancy, suggesting relatively modest
systemic effects of PPARγ inhibition in this study. This conclu-
sion is also confirmed by the absence of any changes in reactivity
and structure of mesenteric arteries of GW9662-treated rats.
Low expression of PPARγ in these vessels compared to uterine
vasculature in part may explain the lack of significant changes in
response to treatment of pregnant rats with GW9662 in our study.
In this regard, a recent study showed that administration of the
PPARγ antagonist T0070907 to pregnant rats using an intraperi-
toneal osmotic mini-pump was associated with a more striking
(by ∼25% vs. ∼10% in our study) reduction in fetal weight, a
modest elevation in blood pressure and reduced sensitivity of
mesenteric arteries to bradykinin (McCarthy et al., 2011a). This
endothelial dysfunction was reproduced by overnight incubation
of mesenteric arteries from healthy pregnant rats with plasma
obtained from T0070907-treated rats. It was suggested that ele-
vated circulating plasma sFlt-1 might be responsible for decreased
vasodilation to bradykinin. Placental of sFlt-1mRNA and protein
were elevated in T0070907-treated rats implicating the placenta
as the main contributor to the increased circulating levels sFlt-1.
Therefore, endothelial dysfunction of maternal mesenteric arter-
ies results from rather indirect effect of PPARγ inhibition in this
study (McCarthy et al., 2011a). In GW9662-treated rats, placental
expression of sFlt-1 was only slightly but not significantly elevated
indicating that this treatment was relatively modest compared to
that described in experiments with administration of T0070907.
This may explain the lack of significant changes in mesenteric
artery vasodilation and consequently, lack of changes in systemic
blood pressure of GW9662-treated rats in our study.
Although we did not find systemic effects of GW9662 admin-
istration, vasodilator function of uteroplacental arteries was
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significantly impaired. It is worth noting that this is the first study
that we are aware of to show an effect of PPARγ inhibition dur-
ing pregnancy on uterine arteries and thus provides evidence
for a vascular mechanism by which PPARγ may influence fetal
growth. These results also suggest that compromised uteroplacen-
tal blood flow may be an early consequence of decreased activity
of PPARγ during pregnancy. In addition, decreased maturation
of trophoblasts in response to PPARγ inhibition (McCarthy et al.,
2011a) may result in diminished remodeling of spiral arteries
and contribute to reduced placental blood flow and fetal growth
restriction found in our study. Under conditions of more severe
reduction in PPARγ activity, we speculate that a greater decrease
in uteroplacental blood flow may result in placental ischemia
followed by increased circulating anti-angiogenic factors and
endothelial dysfunction similar to that found in the recent study
of McCarthy et al. (2011a).
The results of the current study indicate that PPARγ plays
an essential role in the control of uteroplacental vasodilatory
function during pregnancy, an important determinant of blood
flow to the placenta and fetus during pregnancy. Our data
uncover uterine vascular dysfunction as an early mechanism that
may lead to placental hypoperfusion and intrauterine growth
restriction in human pregnancies associated with negative muta-
tions in PPARγ or reduced levels of circulating PPARγ activa-
tors, such as that seen in preeclampsia (Barroso et al., 1999;
Wieser et al., 2008). The use of natural [e.g., relaxin (Chan
and Cipolla, 2011)] or synthetic PPARγ activators, or strategies
directed to increase PPARγ expression or activity in the uterine
vasculature may have important therapeutic potential in treat-
ment of pregnancies complicated by hypertension, diabetes or
preeclampsia.
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